CDTTW
CDT Equity Inc.
Set alert
- YTD
- +93.55%
- 1 year
- +93.55%
- Open
- 0.0119
- Prev close
- 0.006
- Mkt cap
- 5.54K
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0034
- High
- 0.006
- Forward P/E
- 0.00
- Beta
- 2.12
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.00
- 200-d avg
- 0.00
- 1y target
- 0.00
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 2.12
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 433.00K
- Total debt
- 1.27M
- Return on equity
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
About CDT Equity Inc.
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- conduitpharma.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on CDTTW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Highbridge Capital Management, LLC. | 12.25% | 1,620,233 | 11.34K | Sep 29, 2024 |
| Polar Asset Management Partners Inc. | 7.18% | 950,000 | 6.65K | Sep 29, 2024 |
| Saba Capital Management, L.P. | 5.78% | 765,000 | 5.36K | Sep 29, 2024 |
| MMCAP International, Inc. SPC | 5.29% | 700,000 | 4.90K | Sep 29, 2024 |
| Exos Asset Management LLC | 4.19% | 554,646 | 3.88K | Sep 29, 2024 |
| Walleye Capital LLC | 3.90% | 516,032 | 3.61K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AQR Funds-AQR Diversified Arbitrage Fd | 0.52% | 69,216 | 484 | Sep 29, 2024 |
| Saba Capital Income & Opportunities Fd | 0.39% | 51,468 | 360 | Jul 30, 2024 |
| RiverNorth Opportunities Fd | 0.39% | 51,016 | 357 | Sep 29, 2024 |